Synthetic lethality of the ALDH3A1 inhibitor dyclonine and xCT inhibitors in glutathione deficiency-resistant cancer cells

Shogo Okazaki, Subaru Shintani, Yuki Hirata, Kentaro Suina, Takashi Semba, Juntaro Yamasaki, Kiyoko Umene, Miyuki Ishikawa, Hideyuki Saya, Osamu Nagano

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The cystine-glutamate antiporter subunit xCT suppresses iron-dependent oxidative cell death (ferroptosis) and is therefore a promising target for cancer treatment. Given that cancer cells often show resistance to xCT inhibition resulting in glutathione (GSH) deficiency, however, we here performed a synthetic lethal screen of a drug library to identify agents that sensitize the GSH deficiency-resistant cancer cells to the xCT inhibitor sulfasalazine. This screen identified the oral anesthetic dyclonine which has been recently reported to act as a covalent inhibitor for aldehyde dehydrogenases (ALDHs). Treatment with dyclonine induced intracellular accumulation of the toxic aldehyde 4-hydroxynonenal in a cooperative manner with sulfasalazine. Sulfasalazine-resistant head and neck squamous cell carcinoma (HNSCC) cells were found to highly express ALDH3A1 and knockdown of ALDH3A1 rendered these cells sensitive to sulfasalazine. The combination of dyclonine and sulfasalazine cooperatively suppressed the growth of highly ALDH3A1-expressing HNSCC or gastric tumors that were resistant to sulfasalazine monotherapy. Our findings establish a rationale for application of dyclonine as a sensitizer to xCT-targeted cancer therapy.

Original languageEnglish
Pages (from-to)33832-33843
Number of pages12
JournalOncotarget
Volume9
Issue number73
DOIs
Publication statusPublished - 2018 Sep 1

Fingerprint

Sulfasalazine
Glutathione
Neoplasms
Antiporters
Aldehyde Dehydrogenase
Cystine
Poisons
Aldehydes
Anesthetics
Synthetic Lethal Mutations
dyclonine
Glutamic Acid
Stomach
Cell Death
Iron
Growth
Pharmaceutical Preparations

Keywords

  • Drug repurposing
  • Ferroptosis, aldehyde dehydrogenase (ALDH)
  • XCT

ASJC Scopus subject areas

  • Oncology

Cite this

Synthetic lethality of the ALDH3A1 inhibitor dyclonine and xCT inhibitors in glutathione deficiency-resistant cancer cells. / Okazaki, Shogo; Shintani, Subaru; Hirata, Yuki; Suina, Kentaro; Semba, Takashi; Yamasaki, Juntaro; Umene, Kiyoko; Ishikawa, Miyuki; Saya, Hideyuki; Nagano, Osamu.

In: Oncotarget, Vol. 9, No. 73, 01.09.2018, p. 33832-33843.

Research output: Contribution to journalArticle

Okazaki, S, Shintani, S, Hirata, Y, Suina, K, Semba, T, Yamasaki, J, Umene, K, Ishikawa, M, Saya, H & Nagano, O 2018, 'Synthetic lethality of the ALDH3A1 inhibitor dyclonine and xCT inhibitors in glutathione deficiency-resistant cancer cells', Oncotarget, vol. 9, no. 73, pp. 33832-33843. https://doi.org/10.18632/oncotarget.26112
Okazaki, Shogo ; Shintani, Subaru ; Hirata, Yuki ; Suina, Kentaro ; Semba, Takashi ; Yamasaki, Juntaro ; Umene, Kiyoko ; Ishikawa, Miyuki ; Saya, Hideyuki ; Nagano, Osamu. / Synthetic lethality of the ALDH3A1 inhibitor dyclonine and xCT inhibitors in glutathione deficiency-resistant cancer cells. In: Oncotarget. 2018 ; Vol. 9, No. 73. pp. 33832-33843.
@article{76d56e7a7c04498c8086796a9870e23d,
title = "Synthetic lethality of the ALDH3A1 inhibitor dyclonine and xCT inhibitors in glutathione deficiency-resistant cancer cells",
abstract = "The cystine-glutamate antiporter subunit xCT suppresses iron-dependent oxidative cell death (ferroptosis) and is therefore a promising target for cancer treatment. Given that cancer cells often show resistance to xCT inhibition resulting in glutathione (GSH) deficiency, however, we here performed a synthetic lethal screen of a drug library to identify agents that sensitize the GSH deficiency-resistant cancer cells to the xCT inhibitor sulfasalazine. This screen identified the oral anesthetic dyclonine which has been recently reported to act as a covalent inhibitor for aldehyde dehydrogenases (ALDHs). Treatment with dyclonine induced intracellular accumulation of the toxic aldehyde 4-hydroxynonenal in a cooperative manner with sulfasalazine. Sulfasalazine-resistant head and neck squamous cell carcinoma (HNSCC) cells were found to highly express ALDH3A1 and knockdown of ALDH3A1 rendered these cells sensitive to sulfasalazine. The combination of dyclonine and sulfasalazine cooperatively suppressed the growth of highly ALDH3A1-expressing HNSCC or gastric tumors that were resistant to sulfasalazine monotherapy. Our findings establish a rationale for application of dyclonine as a sensitizer to xCT-targeted cancer therapy.",
keywords = "Drug repurposing, Ferroptosis, aldehyde dehydrogenase (ALDH), XCT",
author = "Shogo Okazaki and Subaru Shintani and Yuki Hirata and Kentaro Suina and Takashi Semba and Juntaro Yamasaki and Kiyoko Umene and Miyuki Ishikawa and Hideyuki Saya and Osamu Nagano",
year = "2018",
month = "9",
day = "1",
doi = "10.18632/oncotarget.26112",
language = "English",
volume = "9",
pages = "33832--33843",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "73",

}

TY - JOUR

T1 - Synthetic lethality of the ALDH3A1 inhibitor dyclonine and xCT inhibitors in glutathione deficiency-resistant cancer cells

AU - Okazaki, Shogo

AU - Shintani, Subaru

AU - Hirata, Yuki

AU - Suina, Kentaro

AU - Semba, Takashi

AU - Yamasaki, Juntaro

AU - Umene, Kiyoko

AU - Ishikawa, Miyuki

AU - Saya, Hideyuki

AU - Nagano, Osamu

PY - 2018/9/1

Y1 - 2018/9/1

N2 - The cystine-glutamate antiporter subunit xCT suppresses iron-dependent oxidative cell death (ferroptosis) and is therefore a promising target for cancer treatment. Given that cancer cells often show resistance to xCT inhibition resulting in glutathione (GSH) deficiency, however, we here performed a synthetic lethal screen of a drug library to identify agents that sensitize the GSH deficiency-resistant cancer cells to the xCT inhibitor sulfasalazine. This screen identified the oral anesthetic dyclonine which has been recently reported to act as a covalent inhibitor for aldehyde dehydrogenases (ALDHs). Treatment with dyclonine induced intracellular accumulation of the toxic aldehyde 4-hydroxynonenal in a cooperative manner with sulfasalazine. Sulfasalazine-resistant head and neck squamous cell carcinoma (HNSCC) cells were found to highly express ALDH3A1 and knockdown of ALDH3A1 rendered these cells sensitive to sulfasalazine. The combination of dyclonine and sulfasalazine cooperatively suppressed the growth of highly ALDH3A1-expressing HNSCC or gastric tumors that were resistant to sulfasalazine monotherapy. Our findings establish a rationale for application of dyclonine as a sensitizer to xCT-targeted cancer therapy.

AB - The cystine-glutamate antiporter subunit xCT suppresses iron-dependent oxidative cell death (ferroptosis) and is therefore a promising target for cancer treatment. Given that cancer cells often show resistance to xCT inhibition resulting in glutathione (GSH) deficiency, however, we here performed a synthetic lethal screen of a drug library to identify agents that sensitize the GSH deficiency-resistant cancer cells to the xCT inhibitor sulfasalazine. This screen identified the oral anesthetic dyclonine which has been recently reported to act as a covalent inhibitor for aldehyde dehydrogenases (ALDHs). Treatment with dyclonine induced intracellular accumulation of the toxic aldehyde 4-hydroxynonenal in a cooperative manner with sulfasalazine. Sulfasalazine-resistant head and neck squamous cell carcinoma (HNSCC) cells were found to highly express ALDH3A1 and knockdown of ALDH3A1 rendered these cells sensitive to sulfasalazine. The combination of dyclonine and sulfasalazine cooperatively suppressed the growth of highly ALDH3A1-expressing HNSCC or gastric tumors that were resistant to sulfasalazine monotherapy. Our findings establish a rationale for application of dyclonine as a sensitizer to xCT-targeted cancer therapy.

KW - Drug repurposing

KW - Ferroptosis, aldehyde dehydrogenase (ALDH)

KW - XCT

UR - http://www.scopus.com/inward/record.url?scp=85053438710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053438710&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.26112

DO - 10.18632/oncotarget.26112

M3 - Article

AN - SCOPUS:85053438710

VL - 9

SP - 33832

EP - 33843

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 73

ER -